Aug 1 (Reuters) - Merck KGaA (MRCG.DE), opens new tab is seeing a faster-than-expected improvement in its semiconductor materials business and is aiming to accelerate its drug development pipeline, ...

Merck’s MRK stock has risen 30.4% this year so far compared with an increase of 4.3% for the industry. An ongoing recovery from the disruptions related to the pandemic and strong global underlying ...

Merck MRK boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 40% of its pharmaceutical sales.

Merck has increased its dividend for 14 consecutive years. Its 10-year dividend growth rate of 5.4% is only decent. Merck increased its revenue from $39.5 billion in FY 2015 to $64.2 billion in FY ...

Vree TM for Diabetes 2.0 Helps Patients Manage Their Condition and Facilitates Communication with Healthcare Providers Merck today announced the launch of a mobile application designed to be used by ...